Nine patients in the avelumab monotherapy arm crossed over to the avelumab plus cetuximab group and the median PFS after crossover was 11.3 months (5.8-NR). The median overall survival (OS) of the ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab ...

Avelumab (Bavencio, EMD Serono INc), which is a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for second-line use in patients with locally advanced or metastatic urothelial ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Another year brings another negative avelumab (Bavencio) trial in ovarian cancer, and more experts are left scratching ...

Combination platinum-based chemotherapy is the standard first-line treatment for advanced urothelial carcinoma, but most patients have disease progression within 9 months; the median overall ...

A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1–positive tumors (63.2%), the median ...

Avelumab is an immune checkpoint inhibitor drug that targets a protein found on cancer cells called PD-L1. When PD-L1 binds to a receptor on T cells called PD-1, it acts like a brake, slowing down ...